ABT

Abbott Laboratories' stock price has recently declined, reaching multi-year lows. In November 2025, Abbott agreed to acquire Exact Sciences Corp, which is expected to increase sales but dilute earnings per share. Abbott received FDA approval for its Aveir DR leadless pacemaker system in July 2023 and clearance for its Ultreon 3.0 Software in May 2026. In Q1 2026, Abbott reported adjusted earnings per share that met expectations and revenue that beat estimates, although organic growth was weaker than expected due to issues in the diabetes and respiratory segments.